BR112018017247A2 - ?polinucleotídeo, vetor de ácido nucleico, preparação farmacêutica, kit, e, métodos para fabricar um vetor viral adenoassociado recombinante e para tratar uma doença? - Google Patents
?polinucleotídeo, vetor de ácido nucleico, preparação farmacêutica, kit, e, métodos para fabricar um vetor viral adenoassociado recombinante e para tratar uma doença?Info
- Publication number
- BR112018017247A2 BR112018017247A2 BR112018017247A BR112018017247A BR112018017247A2 BR 112018017247 A2 BR112018017247 A2 BR 112018017247A2 BR 112018017247 A BR112018017247 A BR 112018017247A BR 112018017247 A BR112018017247 A BR 112018017247A BR 112018017247 A2 BR112018017247 A2 BR 112018017247A2
- Authority
- BR
- Brazil
- Prior art keywords
- nucleic acid
- polynucleotide
- kit
- treating
- making
- Prior art date
Links
- 102000039446 nucleic acids Human genes 0.000 title abstract 5
- 108020004707 nucleic acids Proteins 0.000 title abstract 5
- 150000007523 nucleic acids Chemical class 0.000 title abstract 5
- 239000013598 vector Substances 0.000 title abstract 5
- 102000040430 polynucleotide Human genes 0.000 title abstract 4
- 108091033319 polynucleotide Proteins 0.000 title abstract 4
- 239000002157 polynucleotide Substances 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 239000013603 viral vector Substances 0.000 title 1
- 230000002207 retinal effect Effects 0.000 abstract 2
- 208000006992 Color Vision Defects Diseases 0.000 abstract 1
- 201000000761 achromatopsia Diseases 0.000 abstract 1
- 201000007254 color blindness Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
a presente invenção refere-se a um polinucleotídeo configurado para o tratamento de uma doença de células cônicas da retina, tal como acromatopsia, a um vetor de ácido nucleico compreendendo dito polinucleotídeo, a uma composição farmacêutica compreendendo dito vetor de ácido nucleico, a um kit compreendendo dito polinucleotídeo ou dito vetor de ácido nucleico, a um método para fabricar dito vetor de ácido nucleico, e a um método para tratar uma doença das células cônicas da retina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2016/053753 WO2017144080A1 (en) | 2016-02-23 | 2016-02-23 | Gene therapy for the treatment of a disease of retinal cone cells |
| PCT/EP2017/054229 WO2017144610A1 (en) | 2016-02-23 | 2017-02-23 | Gene therapy for the treatment of a disease of retinal cone cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018017247A2 true BR112018017247A2 (pt) | 2019-02-05 |
Family
ID=55521674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018017247A BR112018017247A2 (pt) | 2016-02-23 | 2017-02-23 | ?polinucleotídeo, vetor de ácido nucleico, preparação farmacêutica, kit, e, métodos para fabricar um vetor viral adenoassociado recombinante e para tratar uma doença? |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10849991B2 (pt) |
| EP (1) | EP3419673B1 (pt) |
| JP (1) | JP7005527B2 (pt) |
| CN (1) | CN109310785A (pt) |
| AU (1) | AU2017222948B2 (pt) |
| BR (1) | BR112018017247A2 (pt) |
| CA (1) | CA3015128A1 (pt) |
| DK (1) | DK3419673T3 (pt) |
| ES (1) | ES2835032T3 (pt) |
| IL (1) | IL261295B1 (pt) |
| NZ (1) | NZ745329A (pt) |
| SI (1) | SI3419673T1 (pt) |
| WO (2) | WO2017144080A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012204266C1 (en) * | 2011-01-07 | 2017-12-21 | Applied Genetic Technologies Corporation | Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases |
| GB201800546D0 (en) * | 2018-01-12 | 2018-02-28 | Ucl Business Plc | Treatment |
| GB201900702D0 (en) * | 2019-01-18 | 2019-03-06 | Univ Bristol | Therapy |
| WO2024033837A1 (en) * | 2022-08-11 | 2024-02-15 | Institute Of Molecular And Clinical Ophthalmology Basel (Iob) | Human cone photoreceptor optogenetic constructs |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012204266C1 (en) | 2011-01-07 | 2017-12-21 | Applied Genetic Technologies Corporation | Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases |
| AU2012327236B2 (en) * | 2011-10-28 | 2016-11-10 | University Of Florida Research Foundation, Inc. | Chimeric promoter for cone photoreceptor targeted gene therapy |
| CA2912525A1 (en) * | 2013-05-16 | 2014-11-20 | Applied Genetic Technologies Corporation | Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases |
-
2016
- 2016-02-23 WO PCT/EP2016/053753 patent/WO2017144080A1/en active Application Filing
-
2017
- 2017-02-23 BR BR112018017247A patent/BR112018017247A2/pt unknown
- 2017-02-23 CA CA3015128A patent/CA3015128A1/en active Pending
- 2017-02-23 SI SI201730532T patent/SI3419673T1/sl unknown
- 2017-02-23 NZ NZ745329A patent/NZ745329A/en unknown
- 2017-02-23 JP JP2018562720A patent/JP7005527B2/ja active Active
- 2017-02-23 ES ES17707256T patent/ES2835032T3/es active Active
- 2017-02-23 DK DK17707256.8T patent/DK3419673T3/da active
- 2017-02-23 IL IL261295A patent/IL261295B1/en unknown
- 2017-02-23 EP EP17707256.8A patent/EP3419673B1/en active Active
- 2017-02-23 WO PCT/EP2017/054229 patent/WO2017144610A1/en active Application Filing
- 2017-02-23 AU AU2017222948A patent/AU2017222948B2/en active Active
- 2017-02-23 CN CN201780015487.2A patent/CN109310785A/zh active Pending
-
2018
- 2018-08-22 US US16/109,627 patent/US10849991B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019505238A (ja) | 2019-02-28 |
| AU2017222948A1 (en) | 2018-08-30 |
| US10849991B2 (en) | 2020-12-01 |
| IL261295A (en) | 2018-10-31 |
| IL261295B1 (en) | 2024-04-01 |
| JP7005527B2 (ja) | 2022-02-04 |
| NZ745329A (en) | 2024-03-22 |
| EP3419673A1 (en) | 2019-01-02 |
| EP3419673B1 (en) | 2020-09-02 |
| DK3419673T3 (da) | 2020-11-30 |
| ES2835032T3 (es) | 2021-06-21 |
| CN109310785A (zh) | 2019-02-05 |
| CA3015128A1 (en) | 2017-08-31 |
| AU2017222948B2 (en) | 2021-05-27 |
| SI3419673T1 (sl) | 2021-03-31 |
| WO2017144080A1 (en) | 2017-08-31 |
| WO2017144610A1 (en) | 2017-08-31 |
| US20180353619A1 (en) | 2018-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| BR112018073861A2 (pt) | métodos de terapia de genes para doenças e condições relacionadas com a idade | |
| MX2017013562A (es) | Reguladores de microbioma y usos relacionados de los mismos. | |
| MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
| WO2015117010A3 (en) | Bag3 as a target for therapy of heart failure | |
| BR112017018368A2 (pt) | composições contendo rna para o tratamento de doenças tumorais | |
| BR112017017867A2 (pt) | métodos e composições para tratamento de doenças oculares genéticas | |
| PT3377637T (pt) | Composições para uso em métodos para o tratamento de ferimentos, transtornos e doenças da pele | |
| BR112018017247A2 (pt) | ?polinucleotídeo, vetor de ácido nucleico, preparação farmacêutica, kit, e, métodos para fabricar um vetor viral adenoassociado recombinante e para tratar uma doença? | |
| EA201891399A1 (ru) | Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний | |
| BR112016027871A2 (pt) | composição para melhorar a memória, a função de aprendizado e/ou função cognitiva | |
| BR112016017041A2 (pt) | Proteína isolada tendo atividade de fosfatase, polinucleotídeo, vetor, célula hospedeira, método para produzir uma proteína e composição | |
| EA201692109A1 (ru) | Варианты антител к фактору d и их применение | |
| PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| BR112016019432A8 (pt) | composição terapêutica, kit e seus usos na terapia gênica contra degeneração da retina | |
| BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
| BR112017012581A2 (pt) | tratamento de degeneração da retina com o uso de células progenitoras | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| BR112017005235A2 (pt) | vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc) | |
| BR112018003780A2 (pt) | composições que compreendem um composto de urolitina | |
| BR112018017240A2 (pt) | ?polinucleotídeo, vetor de ácido nucleico, preparação farmacêutica, kit, e, método para fabricar um vetor viral adenoassociado recombinante? | |
| WO2016042561A3 (en) | Downregulating mir-132 for the treatment of lipid related disorders | |
| BR112022001002A2 (pt) | Solvato de dmf, forma a, forma c, processos para a preparação do solvato de dmf, para a preparação da forma a de relugolix anidra, para a preparação da forma b de relugolix anidra e para a preparação da forma c de relugolix anidra, composição farmacêutica, e, método de tratamento de doença | |
| WO2013106766A3 (en) | THERAPEUTIC INDICATIONS OF miR-1291 | |
| PH12018500682A1 (en) | Oxa-diazaspiro compounds having activity against pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |